Showing results (371-380 of 400) with videos related to
Sort By:
Pageof 40
Journal of Medicinal Chemistry|July 19, 1996
N-heteroaryl-2-phenyl-3-(benzyloxy)piperidines: a novel class of potent orally active human NK1 antagonistsT Ladduwahetty, R Baker, M A Cascieri, et al.The Journal of Clinical Investigation|May 20, 2009
Antagonism of T-type calcium channels inhibits high-fat diet-induced weight gain in miceVictor N Uebele, Anthony L Gotter, Cindy E Nuss, et al.Journal of Neurosurgery|July 26, 2024
Preclinical evaluation of transaxial intraputaminal trajectory for enhanced distribution of grafted cells in Parkinson's diseaseMarina E Emborg, Anthony Mancinelli, Julia C Colwell, et al.Thrombosis and Haemostasis|March 20, 2015
Titrating haemophilia B phenotypes using siRNA strategy: evidence that antithrombotic activity is separated from bleeding liabilityJoseph M Metzger, Marija Tadin-Strapps, Anil Thankappan, et al.NPJ Parkinson'S Disease|July 25, 2018
In vivo imaging of inflammation and oxidative stress in a nonhuman primate model of cardiac sympathetic neurodegenerationJeanette M Metzger, Colleen F Moore, Carissa A Boettcher, et al.Bioorganic & Medicinal Chemistry Letters|July 13, 2006
Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivativesLaura C Meurer, Paul E Finke, Karen A Owens, et al.Journal of Environmental Monitoring : JEM|January 24, 2007
An instrumented station for the survey of ozone and climate change in the southern tropicsJ L Baray, J Leveau, S Baldy, et al.Diabetes|January 3, 2012
FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodentsJames Mu, Jason Pinkstaff, Zhihua Li, et al.The Journal of Pharmacology and Experimental Therapeutics|July 20, 2016
The Renal Outer Medullary Potassium Channel Inhibitor, MK-7145, Lowers Blood Pressure, and Manifests Features of Bartter's Syndrome Type II PhenotypeCaryn Hampton, Xiaoyan Zhou, Birgit T Priest, et al.ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of ObesityIyassu K Sebhat, Christopher Franklin, Michael M-C Lo, et al.Pageof 40